Clinical Trial Update: Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations [Phase 4]

View source ↗

Summary

A Phase 4 pilot trial comparing 14-day versus 5-day subcutaneous ACTHAR Gel regimens for multiple sclerosis exacerbations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Acthar Gel (repository corticotropin injection)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Multiple Sclerosis (MS) | Phase 4 | Status: COMPLETED